BrainStorm 10-Q: Going Concern, Material Weakness, and New Litigation
BCLI has more than doubled off its 52-week low of $0.459 on elevated volume (2.5× avg).
Summary
BrainStorm's Q2 2026 10-Q reveals a going concern warning, a material weakness in internal controls, new litigation, and additional convertible debt issued after quarter-end.
Key Events · Earnings and Guidance · BCLI
-
Going Concern Warning
Cash and cash equivalents fell to $209K as of June 30, 2026, from $276K at year-end 2025. Management states substantial doubt about the company's ability to continue as a going concern.
-
Material Weakness Disclosed
Management identified a material weakness in internal control over financial reporting related to short-term loans initiation, review, authorization and execution controls.
-
New Litigation
Sourasky University Medical Center filed a claim seeking NIS 2,117,950 (~$0.7M) for alleged unpaid clean room fees. The company has already accrued $570K in overdue rent as trade payables.
-
Subsequent Convertible Notes
After quarter-end, the company issued two convertible promissory notes totaling $266.8K in principal ($221.5K net proceeds) with original issue discounts and conversion features.
Analysis · BCLI · Life Sciences
BrainStorm Cell Therapeutics reported a $3.9M net loss for Q2 2026 with only $209K in cash and cash equivalents, down from $276K at the start of the year. The company explicitly states substantial doubt about its ability to continue as a going concern. Management also disclosed a material weakness in internal controls over short-term loan processes, a new $0.7M lawsuit from Sourasky Medical Center, and subsequent convertible note issuances totaling $266.8K in principal. The combination of a near-empty balance sheet, internal control failures, and mounting litigation makes this a critical update for investors.
At the time of this filing, BCLI was trading at $0.99 on OTC in the Life Sciences sector, with a market capitalization of approximately $10.9M. The 52-week trading range was $0.46 to $1.69. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.